ImmunityBio
ImmunityBio's revenue rose 668.3% to $113 million in fiscal 2025. Its operating margin was −226.0%, up from −2,334.2% a year earlier. Free cash flow was −$309 million. The diluted share count rose 31.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What ImmunityBio does
ImmunityBio is a biotechnology company that develops treatments to help the immune system fight cancer and some infectious diseases. Its first and only approved product, ANKTIVA, is a protein that activates certain immune cells. It is used together with the standard BCG treatment for adults with non-muscle invasive bladder cancer that no longer responds to BCG.
ANKTIVA is approved in the United States, the United Kingdom and Saudi Arabia, and received conditional approval in the European Union in February 2026. In Saudi Arabia it also has conditional approval for use with other drugs in a form of metastatic lung cancer. The company is trying to win approval for more uses, including bladder tumors with papillary growths and lung cancer.
It has many other candidates in development, grouped under a platform it calls Cancer BioShield. The company has a financing agreement with Oberland, called the RIPA, under which it must make payments, and it also owes money on a promissory note to a related party.
Its biggest risks, as it describes them
- It has a single approved product and limited experience selling medicines.
- Payment obligations under its RIPA financing agreement could hurt its finances and its ability to raise money.
- The RIPA includes operating limits and default events that could keep it from pursuing opportunities.
- It may not win approval of ANKTIVA for more uses or sell it successfully in new markets.
- Its reliance on third parties and the cost of raising money through shares, debt or licenses.
Income statement
ImmunityBio lost money in fiscal 2025: a net loss of $351 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 317 | 107 | 266 | 150 | 243 |
| Debt incl. finance leases | — | 673 | 577 | 0 | 0 |
| Net debt (negative means net cash) | — | 566 | 310 | −150 | −242 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −22.2x | −5.5x | −2.8x | −3.0x | −4.2x |
| Current ratio | 0.9x | 0.3x | 5.0x | 3.4x | 5.1x |
| Quick ratio | 0.9x | 0.3x | 5.0x | 3.2x | 5.1x |
Cash flow
Projections
Project ImmunityBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought ImmunityBio shares on the open market, and 3 insiders sold $8.4 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Cheryl CohenDirector | Sold plan | 131,210 | $9.50 | $1.2 million | Form 4 |
| Jul 1, 2026 | Christobel SeleckyDirector | Sold plan | 159,478 | $9.02 | $1.4 million | Form 4 |
| Jun 30, 2026 | Christobel SeleckyDirector | Sold plan | 1,000 | $9.00 | $9,000 | Form 4 |
| Jun 29, 2026 | Christobel SeleckyDirector | Sold plan | 95,722 | $9.01 | $862,455 | Form 4 |
| Jun 24, 2026 | Barry J. SimonDirector | Sold plan | 25,000 | $7.88 | $197,000 | Form 4 |
| Jun 4, 2026 | Barry J. SimonDirector | Sold plan | 23,033 | $7.18 | $165,377 | Form 4 |
| Feb 24, 2026 | Barry J. SimonDirector | Sold plan | 75,000 | $12.01 | $900,750 | Form 4 |
| Feb 23, 2026 | Barry J. SimonDirector | Sold plan | 165,000 | $10.25 | $1.7 million | Form 4 |
| Feb 23, 2026 | Christobel SeleckyDirector | Sold plan | 25,000 | $10.00 | $250,000 | Form 4 |
| Feb 20, 2026 | Barry J. SimonDirector | Sold plan | 10,000 | $9.25 | $92,500 | Form 4 |
| Jan 20, 2026 | Barry J. SimonDirector | Sold plan | 151,967 | $7.20 | $1.1 million | Form 4 |
| Jan 20, 2026 | Christobel SeleckyDirector | Sold plan | 25,000 | $7.51 | $187,750 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 3 of 9 |
| Rule of 40 | −63,722.0% | −429.5% | 395.8% |
| Altman Z'' | −21.46 | −33.14 | −24.85 |
| Accruals ratio | −49.9% | −5.0% | −10.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 4 of 9 | 3 of 9 |
Compare
Put ImmunityBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | |
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | Compare |
| Xencor | FY25 | 13.7% | −141.3% | −110.1% | −19.9% | — | 3 | Compare |
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | Compare |
| Cytokinetics | FY25 | 376.6% | −695.4% | −607.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 15 | 113 |
| Revenue growth | −81.4% | 2.3% | 4.4% | 4,585.1% | −72.5% | 54.4% | −74.3% | 159.2% | 2,270.6% | 668.3% |
| Gross profit | — | — | — | — | — | — | 0 | 1 | 15 | 112 |
| Research and development | 29 | 42 | 56 | 112 | 140 | 196 | 248 | 232 | 190 | — |
| Operating income | −124 | −99 | −98 | −156 | −221 | −330 | −351 | −362 | −344 | −256 |
| Net income | −121 | −96 | −96 | −158 | −222 | −347 | −417 | −583 | −414 | −351 |
| Diluted EPS (US$) | −1.47 | −1.20 | −1.22 | −0.43 | −0.59 | −0.89 | −1.04 | −1.15 | −0.62 | −0.38 |
| Diluted shares (millions) | 82 | 81 | 79 | 366 | 377 | 389 | 400 | 509 | 700 | 920 |
| Cash flow | ||||||||||
| Cash from operations | −39 | −49 | −63 | −152 | −172 | −274 | −338 | −367 | −391 | −305 |
| Capital expenditure | 7 | 35 | 13 | 4 | 2 | 34 | 78 | 31 | 7 | 4 |
| Free cash flow | −45 | −84 | −76 | −156 | −173 | −308 | −416 | −397 | −398 | −309 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 16 | 15 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Stock-based compensation | 74 | 37 | 23 | 3 | 2 | 57 | 40 | 49 | 34 | 37 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 199 | 128 | 74 | 112 | 96 | 317 | 107 | 266 | 150 | 243 |
| Debt incl. finance leases | — | — | — | — | — | — | 673 | 577 | 0 | 0 |
| Total assets | 318 | 250 | 182 | 143 | 221 | 469 | 362 | 504 | 383 | 502 |
| Total liabilities | 24 | 32 | 36 | 22 | 340 | 713 | 812 | 1,090 | 871 | 1,002 |
| Shareholders' equity | 293 | 219 | 146 | 121 | −120 | −242 | −447 | −587 | −489 | −500 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 99.3% |
| Operating margin | −282,954.5% | −220,266.7% | −209,338.3% | −7,095.9% | −36,509.1% | −35,361.9% | −146,374.2% | −58,239.6% | −2,334.2% | −226.0% |
| Net margin | −274,565.9% | −214,273.3% | −204,736.2% | −7,165.2% | −36,669.6% | −37,129.6% | −173,569.6% | −93,761.4% | −2,804.8% | −310.2% |
| Free cash flow margin | −102,620.4% | −185,766.7% | −162,729.8% | −7,102.4% | −28,660.0% | −32,974.5% | −173,196.2% | −63,881.2% | −2,700.1% | −272.6% |
| Rule of 40 (growth + FCF margin) | −102,701.8% | −185,764.4% | −162,725.3% | −2,517.3% | −28,732.5% | −32,920.1% | −173,270.5% | −63,722.0% | −429.5% | 395.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −37.2% | −37.6% | −52.8% | −118.3% | — | — | — | — | — | — |
| Return on assets | −35.3% | −34.0% | −44.5% | −97.1% | −121.7% | −100.5% | −100.2% | −134.6% | −93.2% | −79.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |